Drug Profile
Research programme: matrix metalloprotease inhibitors - LEO Pharma
Alternative Names: matrix metalloprotease inhibitors research programme - LEO PharmaLatest Information Update: 13 May 2003
Price :
$50
*
At a glance
- Originator LEO Pharma
- Class
- Mechanism of Action Matrix metalloproteinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 13 May 2003 Discontinued - Preclinical for Cancer in Denmark (unspecified route)
- 19 Sep 2002 Preclinical trials in Cancer in Denmark (unspecified route)